



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
(Case No. 97-002-L)

1654
PATENT *[Signature]*

In the Application of:

Krafft et al.

Serial No.: 09/745,057

Filing Date: December 20, 2000

For: Amyloid β Protein (Globular
Assembly and Uses Thereof)

Examiner: M. Audet

Group Art Unit: 1654

Confirmation No.: 8012

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. §§ 1.97 - 1.99, the applicants wish to make the references identified on the attached Form SB08 of record in the application identified above. This Information Disclosure Statement is in compliance with the continuing duty of candor as set forth in 37 C.F.R. § 1.56. Pursuant to 37 C.F.R. § 1.98(d), copies of the references are not provided at this time, since they were previously filed in the parent application.

A fee of \$180.00 is required. The undersigned attorney by his signature authorizes any such fee to be debited from Deposit Account 13-2490.

Respectfully submitted,
McDonnell Boehnen Hulbert & Berghoff LLP

Date: November 16, 2004


By:

Mark L. Chael
Mark L. Chael
Reg. No. 44,601

Telephone: 312-913-0001
Facsimile: 312-913-0002

McDonnell Boehnen Hulbert & Berghoff LLP
300 South Wacker Drive
Chicago, IL 60606

11/22/2004 SSESHE1 00000036 132490 09745057
01 FC:1806 180.00 DA



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
(Case No. 97-002-L)

PATENT

In the Application of:

Krafft et al.

Serial No.: 09/745,057

Filing Date: December 20, 2000

For: Amyloid β Protein (Globular
Assembly and Uses Thereof)

Examiner: M. Audet

Group Art Unit: 1654

Confirmation No.: 8012

TRANSMITTAL LETTER

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

In regard to the application identified above,

1. We are transmitting herewith the attached:

- a) Information Disclosure Statement;
- b) Form SB08; and
- c) return receipt postcard.

2. With respect to fees:

- a) Please charge \$180.00 to our Deposit Account, No. 13-2490.
- b) Please charge any underpayment or credit any overpayment to our Deposit Account, No. 13-2490.

3. CERTIFICATE OF MAILING UNDER 37 CFR § 1.8: The undersigned hereby certifies that this Transmittal Letter and the documents identified above are being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450 on November 16, 2004.

Date: November 16, 2004

Respectfully submitted,

Mark L. Chael, J.D., Ph.D.
Registration No. 44,601



INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Sheet	2	of	6	Application No.	09/745,057
				Filing Date:	December 20, 2000
				First Named Inventor	Krafft
				Group Art Unit	1654
				Examiner Name	Audet
				Attorney Docket No.	97-002-L

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		Burdick et al., Assembly and Aggregation Properties of Synthetic Alzheimer's A4/B Amyloid Peptide Analogs', The Journal of Biological Chemistry, pp. 546-554.	
		Busciglio et al., (1995). β -Amyloid Fibrils Induce Tau Phosphorylation and Loss of Microtubule binding. Neuron 14, 879-888.	
		Cai, S.D. et al., (1993). Release of Excess Amyloid Beta Protein From a Mutant Amyloid Beta Protein Precursor. Science 259, 514-516.	
		Chartier-Harlan et al., (1991) Early-onset Alzheimer's Disease Caused by Mutation at Codon 717 of the β -Amyloid Precursor Protein nature, 353, 844-6.	
		Citron, et al., (1992) Mutation of the Amyloid Precursor Protein in Familial Alzheimer's Disease Increases Beta Protein Production. Nature, 360, 672-674.	
		Esch, et al., (1990) Cleavage of Amyloid Beta Peptide During Constitutive Processing of its Precursor, Science 248, 1122-1124.	
		Glenner, et al., (1984) Alzheimer's Disease Initial Report of the Purification and Characterization of a Novel Cerebro Vascular Amyloid. Biochem Biophys Res Commun 120, 885-890.	
		Glenner et al., (1984) Alzheimer's Disease and Downs Syndrome Sharing of a Unique Cerebrovascular Amyloid Fibril Protein. Biochem Biophys Res Commun 122, 1131-1135.	
		Goate, et al., (1991) Segregation of a Missense Mutation in the Amyloid Precursor Protein Gene with Familial Alzheimer's Disease. Nature, 349, 704-6.	
		Halverson et al., Molecular Determinants of Amyloid Deposition in Alzheimer's Disease: Conformational Studies of Synthetic B-Protein Fragments, Biochemistry, Vol. 29, pp. 2639-2644.	
		Iversen, L.L., et al., (1995) The toxicity in vitro of β -amyloid protein. Biochem 311, 1-16.	
		Kang, et al., (1987) Nature 325, 733-736.	
		Ladror, et al., (1994) Cleavage at the Amino and Carboxy Termini of Alzheimer's Amyloid- β by Cathepsin D., J. Biol. Chem. 269, 18422-8	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English translation is attached.



INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application No.	09/745,057
Filing Date:	December 20, 2000
First Named Inventor	Krafft
Group Art Unit	1654
Examiner Name	Audet
Attorney Docket No.	97-002-L

Sheet	3	of	6
-------	---	----	---


OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		Ladu, et al., Isoform-Specific Binding of Apolipoprotein-E to Beta-Amyloid. (1994) J. Biol. Chem. 269, 23403-23406.	
		Ladu, et al., (1994) Purification of Apolipoprotein-E Attenuates Isoform-Specific Binding to Beta-Amyloid. J. of Biol. Chem. 269, 9039-9042.	
		Lambert, et al., (1994) b/A4 /Evoked Degeneration of Differentiated SH-Sy5Y Human Neuroblastoma Cells. J. Neurosci. Res. 39, 377-384.	
		Levine, Harry, soluble Multimeric Alzheimer. Beta. (1-40) Pre-amyloid Complexes in Dilute Solution', Neurobiology by Aging, Vol. 16, No. 5, pp. 755-764.	
		Levy Lahad E., et al., (1995) A Familial Alzheimer's Disease Locus on Chromosome 1. Science 269, 970-973.	
		Lorenzo, et al., (1994) β -Amyloid neurotoxicity requires fibril information and is inhibited by Congo red. Proc. Natl. Acad Sci 91, 12243-12247.	
		Ma J., et al., (1994) The amyloid-associated proteins a1-antichymotrypsin, and apolipoprotein E promote the assembly of the Alzheimer β -protein into filaments. Nature 372, 92-94.	
		Mann, et al., (1996) Amyloid beta Protein (Abeta) deposition in chromosome, 14-linked Alzheimer's disease: predominance of Abeta42(43). Annals of Neurology 40, 149-56.	
		Masters, et al., (1985) Neuronal Origin of a Cerebral Amyloid. Neurofibrillary Tangles of Alzheimer's Disease Contain the Same Protein as the Amyloid of Plaque Cores and Blood Vessels. EMBOJ. 4 2757-2764.	
		Masters, et al., (1985) Amyloid Plaque Core Protein in Alzheimer's Disease and Down Syndrom. Proc Natl Acad Sci USA 82, 4245-4249.	
		May, et al., (1992) β -Amyloid Peptide in Vitro Toxicity: Lot-to-Lot Variability. Neurobiol Aging 13, 605-607.	
		Mullan, M. (1992) A Pathogenic Mutation for Probable Alzheimer's-Disease in the APP Gene at the N-Terminus of Beta-Amyloid. Nature Genetics 1, 345-347.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English translation is attached.



INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application No.	09/745,057					
	Filing Date:	December 20, 2000				
		First Named Inventor	Krafft			
			Group Art Unit	1654		
				Examiner Name	Audet	
Attorney Docket No.	97-002-L					

Sheet 4 of 6


OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		Murrell, et al., (1991) A mutation in the Amyloid Precursor Protein Associated with Hereditary Alzheimer's Disease. Science, 254, 97-9.	
		Namgung, et al., (1995) Long-term potentiation in vivo in the intact mouse hippocampus. Brain Research 689, 85-92.	
		Oda, et al., (1994) Purification and Characterization of Brain Clusterin. Biochem. Biophys. Res. Commun., 204, 1131-1136.	
		Oda, et al., (1995) Clusterin (apoJ) Alters the Aggregation of Amyloid β -Peptide ($A\beta$ 1-42) and Forms Slowly Sedimenting $A\beta$ /Clusterin complexes that cause Oxidative Stress, Exptl. Neurology, 136, 22-31.	
		Pike, et al., (1993) Neurodegeneration Induced by β -Amyloid Peptides in vitro: The Role of Peptide Assembly State. The Journal of Neuroscience 13(4), 1676-1687	
		Roher, et al., (1993) Morphological and biochemical analyses of amyloid plaque core proteins purified from Alzheimer's disease brain tissue. Neurochem 61, 1916-1926.	
		Scheuner, et al., (1996) Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nature Medicine 2, 864-70.	
		Selkoe, D. J., (1994) Normal and abnormal biology of the beta-amyloid precursor protein. Cowan, W.M. (Ed.) Annual Review of Neuroscience, Vol. 17. ix+623p. Annual Reviews Inc.: Palo Alto, California, USA., 489-517.	
		Sherrington, et al., (1995) Cloning a gene bearing missense mutation in early onset familial Alzheimer's disease. Nature 375, 754-760.	
		Simmons, et al., (1994) Secondary Structure of Amyloid β Peptide Correlates with Neurotoxic Activity in vitro. Molecular Pharmacology 45, 373-379.	
		Sisodia, et al., (1990) Evidence that Beta Amyloid Protein in Alzheimer's Disease is Not Derived By Normal Processing. Science 248, 492-495.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English translation is attached.



INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

.Sheet 5 of 6	Application No.	09/745,057	
	Filing Date:	December 20, 2000	
	First Named Inventor	Krafft	
	Group Art Unit	1654	
	Examiner Name	Audet	
		Attorney Docket No.	97-002-L

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		Snow, et al., A Rat Model to Study the Effects of BAP-Containing Amyloid in Brain. ("Brain amyloid accumulation in rats within 1 week of infusion of amyloid- β and a plaque component") (1992) Soc. Neurosci. Abstr. 18, 1465, Ab. 616.6.	
		Snyder, et al., (1994) Amyloid β Aggregation: Selective Inhibition of Aggregation in Mixtures of Amyloid with Different Lengths. Biophys. J. 67, 1216-28.	
		Strittmatter, W.J., et al., (1993) Apolipoprotein E: High-avidity binding to β -amyloid and increases frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci 90, 1977-1981.	
		Suzuki, et al., (1994) An increased percentage of long amyloid β protein secreted by familial amyloid protein precursor (beta-APP-717) mutants. Science 264, 1336-1340.	
		Tamaoka, et al., (1994) Biochemical Evidence for the Long-Tail Form (A β -1-42-43) of Amyloid-Beta Protein as a Seed Molecule in Cerebral Deposits of Alzheimer's Disease, Biochem. Biophys. Res. Commun. 205, 834-842.	
		Tanzi et al., (1987) Amyloid Beta Protein Gene complementary DNA, mRNA Distribution and Genetic Linkage Near the Alzheimer Locus. Science 235, 880-884.	
		Wright et al., (1993) Neuroglial cholinesterases in the normal brain and in Alzheimer's Disease: relationship to plaques, tangles and patterns of selective vulnerability. Ann Neurol 34, 373-384.	
		Yankner, B.A., (1996) Mechanisms of Neuronal Degeneration in Alzheimer's Disease. Neuron 16, 921-932.	
		Zhang, et al., (1994) Focal Adhesion Kinase Expressed by Nerve Cells Lines Shows Increased Tyrosine Phosphorylation in Response to Alzheimer's A β Peptide. The Journal of Biological Chemistry 269, 25247-25250.	
		Kuo, et al., (1996) Water-soluble A β - (N-40, N-42) Oligomers in Normal and Alzheimer Disease Brains. The Journal of Biological Chemistry, 271(8), 4077,4081.	
		Roher, et al., (1993) β -Amyloid-(1-42) is a major component of cerebrovascular amyloid deposits: Implication for the pathology of Alzheimer disease. Biochemistry, 90, 10836-10840.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English translation is attached.



INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application No.	09/745,057
Filing Date:	December 20, 2000
First Named Inventor	Krafft
Group Art Unit	1654
Examiner Name	Audet
Attorney Docket No.	97-002-L

Sheet 6 of 6

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		Roher, et al., (1996) Morphology and toxicity of ABeta-(1-42) Dimer Derived from Neuritic and Vascular Amyloid Deposits of Alzheimer's Disease. The Journal of Biological Chemistry, 271(34), 20631-20635.	
		Wisniewski, et al., (1994) Alzheimer's Disease and Soluble A β . Neurobiology of Aging, 15(2), 143-152.	
		Database Caplus on STN. No. 1993:623307. chauhan et al. Dual Modulation of Protein Kinase C Activity by Amyloid Beta Protein, abstract.	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English translation is attached.